Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy

This study has been completed.
Sponsor:
Collaborators:
Adult AIDS Clinical Trials Group
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00851786
First received: February 25, 2009
Last updated: February 20, 2014
Last verified: February 2014
  Purpose

Herpes zoster, or shingles, is the result of a viral infection that causes a painful skin rash, usually in older people or people with suppressed immune systems like those infected with HIV. The ZOSTAVAX vaccine has been shown to reduce the number of infections and symptoms of herpes zoster infection in people over the age of 60. The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of two doses of ZOSTAVAX in HIV-1-infected adults with conserved immune function (Cd4+ T cell counts >=200 cells/uL) virologically suppressed on potent combination antiretroviral therapy (ART).


Condition Intervention Phase
Herpes Zoster
HIV Infections
Biological: ZOSTAVAX
Biological: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
Official Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX® (Zoster Vaccine Live) in Human Immunodeficiency Virus (HIV)-1-Infected Adults on Potent Combination ART With Conserved Immune Function

Resource links provided by NLM:


Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures:
  • Number of Participants With Composite Safety Endpoint of the Occurrence of Serious Adverse Events (SAEs) or Division of AIDS (DAIDS) Grade 3 and 4 Signs and Symptoms, Excluding SAEs Related to Trauma [ Time Frame: During the 6 week study period after receipt of any dose of ZOSTAVAX ] [ Designated as safety issue: Yes ]
    Although the study was designed as a randomized trial, it was not powered to detect safety related differences between treatment arms. The safety of ZOSTAVAX was determined by comparing the number of subjects from the active arm who experienced safety endpoint to the number from a pre-specified decision rule, which was calculated based on a similar population and calibrated using the number of safety endpoints observed from the placebo arm. The pre-specified decision rule is that ZOSTAVAX would be considered to have acceptable safety if no more than 18 subjects experience a study-defined composite safety endpoint.


Secondary Outcome Measures:
  • VZV Antibodies as Measured by gpELISA [ Time Frame: Within 6 weeks following one or two doses of ZOSTAVAX ] [ Designated as safety issue: No ]
    VZV antibody titer measured by gpELISA after one or two doses of ZOSTAVAX/placebo

  • VZV-specific Cellular Immune Responses by Intracellular Cytokine Staining and/or ELISPOT Assays in the First 40 Subjects Entering in Each CD4 Stratum at the Opening of Stage II [ Time Frame: Within 6 weeks following one or two doses of ZOSTAVAX ] [ Designated as safety issue: No ]

Enrollment: 395
Study Start Date: April 2009
Study Completion Date: December 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Participants with CD4 cell counts of 200 cells/uL or greater in Stages 1 and 2, stratified by CD4 cell counts (200-349 cells/uL vs. >=350 cells/uL), will be given one dose of ZOSTAVAX (Zoster Vaccine Live) at Day 0 and Week 6 and will be followed for at least 42 days after each vaccination after which a safety assessment will be conducted.
Biological: ZOSTAVAX
Subcutaneous injection of 0.65 mL of ZOSTAVAX at Day 0 and Week 6
Placebo Comparator: 2
Participants with CD4 cell counts of 200 cells/uL or greater in Stages 1 and 2, stratified by CD4 cell counts (200-349 cells/uL vs. >=350 cells/uL), will be given one dose of placebo at Day 0 and Week 6 and will be followed for at least 42 days after each vaccination after which a safety assessment will be conducted
Biological: Placebo
Subcutaneous injection of 0.65 mL of placebo at Day 0 and Week 6

Detailed Description:

The varicella-zoster virus (VZV) which causes herpes zoster (HZ), or shingles, is associated with a painful skin rash and post-herpetic neuralgia (PHN). The incidence and severity of HZ and PHN increase as immune function decreases, as in elderly or HIV-infected people. The live VZV vaccine, ZOSTAVAX, has been shown to reduce the incidence and severity of HZ and PHN in people over the age of 60. The main purpose of this study is to determine whether a two-dose regimen of ZOSTAVAX is safe and well-tolerated in HIV-infected individuals with conserved immune function.

This study has two stages and two arms. It may last up to 24 weeks per subject. In Stage 1, 48 participants with CD4 cell counts of 200 or more cells/uL will be enrolled (24 participants with a CD4 count between 200 and 349 cells/uL and 24 participants with a CD4 count equaling 350 or more cells/uL). These participants will be randomized 3:1 to receive two doses of ZOSTAVAX or placebo at least six weeks apart. If certain safety criteria are met for Stage 1, enrollment will be opened to Stage 2. Stage 2 will enroll approximately 352 subjects with CD4+ T cell counts >= 200 cells/uL. In Stage 2, participants will be stratified using the same parameters as Stage 1 and will then be randomized 3:1 to receive either two doses of vaccine or placebo according to the same schedule. Participants will be followed for at least 42 days after each vaccination. Temperatures will be collected daily for 42 days following each vaccination. Telephone contact will also be made 2 to 3 days after each vaccination and at 24 weeks following the initial vaccination to obtain information regarding vaccination-related symptoms.

All participants will have between 6 and 8 study visits. At the screening visit, documentation of HIV status is required, and blood and urine collection, a physical exam, medical history, and clinical assessment will occur. At each visit, a targeted physical exam will occur. At some visits, blood and urine collection, and a clinical assessment will occur. Antiretroviral medications are not provided by this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HIV infected
  • Use of potent combination ART regimen within 90 days prior to entry and undetectable plasma HIV RNA level within 90-210 days prior to study entry
  • CD4 cell count of at least 200 cells/uL obtained within 30 days prior to study entry
  • Laboratory values obtained within 90 days prior to study entry

    • Hemoglobin 7.0 g/dL or greater
    • Platelet count 50,000/mm3 or greater
    • Creatinine 3 x ULN or less
    • AST (SGOT), ALT (SGPT), and alkaline phosphatase 5 x ULN or less
  • For females of reproductive potential, a negative serum or urine pregnancy test within 24 hours prior to study entry
  • Willing to use accepted forms of contraception for the duration of the study
  • History of varicella or herpes zoster more than 1 year prior to vaccination or VZV seropositivity at any time prior to entry
  • Men and women age >=18 years
  • Ability and willingness of subject or legal guardian/representative to provide informed consent

Exclusion Criteria:

  • History of nadir CD4+ count <100 cells/uL
  • Known or suspected immune dysfunction caused by a medical condition or any cause other than HIV infection, such as congenital immunodeficiency, organ or bone marrow transplantation, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, or generalized malignancy [NOTE: Subjects with prostate or breast cancer who are not on chemotherapeutic drugs (other than hormone blocking drugs), subjects with skin cancer or Kaposi's sarcoma limited to skin who are not receiving radiation therapy or chemotherapy, and subjects with a history of other malignancies who have been disease-free for at least 5 years will be eligible for enrollment.]
  • Receipt of any varicella or zoster vaccine prior to study entry
  • History of allergy/sensitivity, or hypersensitivity to any vaccine component, including gelatin or neomycin
  • Receipt of immunoglobulin or any blood products, other than autologous blood transfusion, given during the 5 months prior to study entry or expected during the 24-week study period
  • Receipt of any live virus vaccine within 28 days prior to study entry or during study period
  • Receipt of any inactivated vaccine within 7 days prior to study entry or during study period
  • Scheduled administration of any live virus vaccine or inactivated vaccine at or between study entry and the Week 12 visit
  • Participation in an investigational drug study within the last 30 days prior to study entry
  • Use of immunosuppressive therapy. More information can be found in the protocol.
  • Any chronic suppressive antiviral therapy with activity against herpes viruses, including but not limited to acyclovir, famciclovir, valacyclovir, ganciclovir, foscarnet, and cidofovir within 7 days prior to study entry or expected use through the 24-week study period except where necessary for acute treatment of intercurrent viral infection.
  • Any episode of VZV reactivation in the 12 months prior to study entry
  • Active drug or alcohol use, dependence, or any other reason that, in the opinion of the site investigator, would interfere with the study
  • Pregnancy (including subjects who are expecting to conceive within 3 months of the second vaccination) or breast feeding
  • Any acute intercurrent illness that might interfere with the interpretation of the study
  • Significant underlying illness preventing completion of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00851786

  Show 43 Study Locations
Sponsors and Collaborators
Adult AIDS Clinical Trials Group
Merck Sharp & Dohme Corp.
Investigators
Study Chair: Constance A. Benson, MD University of California, San Diego
Study Chair: Jeffrey L. Lennox, MD Emory University
  More Information

Publications:

Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT00851786     History of Changes
Other Study ID Numbers: A5247, 10519, ACTG A5247
Study First Received: February 25, 2009
Results First Received: September 7, 2012
Last Updated: February 20, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Herpes Zoster Vaccine
Herpes Zoster Virus
HIV

Additional relevant MeSH terms:
Herpes Zoster
Acquired Immunodeficiency Syndrome
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Herpesviridae Infections
DNA Virus Infections

ClinicalTrials.gov processed this record on July 22, 2014